BioCentury

7:00 AM GMT, Oct 4, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

Restructuring watch

Restructuring watch

Date Company Staff cuts Cash Yrs cash pre-cut Cash date 1H10 oper loss
7/15/10 Adolor Corp. (NASDAQ:ADLR) 30% to ~80 $62.3 1.73 6/30/10 $18.0
Focusing on two programs: marketed drug Entereg alvimopan, a selective peripherally acting mu opioid receptor antagonist co-promoted in the U.S. for postoperative ileus (POI) with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); and its opioid bowel dysfunction

Read the full 745 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.